Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 14Neoplasms 11Lung Neoplasms 11Neoplasm Metastasis 7Breast Neoplasms 6Brain Neoplasms 6Head and Neck Neoplasms 4Gliosarcoma 4Glioblastoma 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Prostatic Neoplasms 2Oligodendroglioma 2Non-Squamous Non-Small Cell Lung Cancer 2Glioma 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metaplasia × Erlotinib Hydrochloride × Clear all
NCT01013831 2015-02-18

Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung

National Cancer Institute (NCI)

Phase 1 Terminated
60 enrolled

Metaplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡